Literature DB >> 14962225

Hepatitis C virus quasispecies in the natural course of HCV-related disease in patients with haemophilia.

G Tagariello1, M Gerotto, P Pontisso, D Belvini, R Salviato, P Radossi, A Alberti.   

Abstract

Patients with haemophilia show high prevalence of hepatitis C infection but low rate of progressive liver disease when they are not co-infected with HIV. The balance between host immune system and hepatitis C virus (HCV) variability seems to play a major role in the evolution of the HCV-related disease. To address this point we have studied, in a group of selected patients with haemophilia, the composition and in some cases the evolution, of the highest variable envelope gene within the hypervariable region 1 (HVR1) of the HCV, which is the region more directly exposed to the host immune response. Five of 12 patients show a very high homogeneity of the HVR1 and four of those had severe progressive liver disease. These results seem to confirm the major role of the immunity in driving the variability of the HCV rather than the high degree of different HCV strains to which haemophiliacs have been in touch with, during their long-term replacement therapy. Our results seem in keeping with other studies on different type of patients, where a low degree of quasispecies variability has been demonstrated in relationship with the progression and the severity of their liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14962225     DOI: 10.1046/j.1365-2516.2003.00846.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  2 in total

1.  Hepatitis C hypervariable region 1: association of reduced selection pressure in african americans with treatment failure.

Authors:  Vicki M Park; Barbara C Mason; Julia Krushkal; Rongling Li; Caroline Riely; Jaquelyn Fleckenstein
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

Review 2.  The epidemiology of hepatitis C infection in the United States.

Authors:  Vinod K Rustgi
Journal:  J Gastroenterol       Date:  2007-07-25       Impact factor: 7.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.